Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and/or undergoing percutaneous coronary intervention

Miroslav Mihajlović¹,², Milan Marinković², Monika Kozieł³, Nebojša Mujović¹,², Gregory Y.H. Lip¹,³, Tatjana S. Potpara¹,²

¹ School of Medicine, Belgrade University, Belgrade, Serbia
² Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia
³ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
⁴ Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland

Introduction  Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia, with an estimated global prevalence of 3% in adults.¹ The prevalence of AF is increasing with age, ranging from 0.16% in those younger than 35 years to approximately 14% in those older than 85 years.¹ The principal therapy for prevention of cardioembolic stroke or systemic embolism in AF is oral anticoagulant (OAC) therapy, which includes vitamin K antagonist (VKA) oral anticoagulants or non–vitamin K antagonist oral anticoagulants (NOACs).² Hence, efforts are being made to improve uptake of stroke prevention in AF and to ensure persistence with therapy once initiated.³,⁴ Given that AF and coronary artery disease (CAD) share many common risk factors, they often coincide, with the reported prevalence of CAD in patients with AF ranging from 6.4% to 46.5%.⁵,⁶ The presence of CAD increases the risk of AF-related stroke.⁷

Patients with AF presenting with acute coronary syndrome (ACS) or undergoing elective percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT), including aspirin and a P2Y12 inhibitor to prevent stent thrombosis and recurrent coronary ischemia, and OACs for the prevention of AF-related cardioembolic stroke or systemic embolism (that is, triple antithrombotic therapy [TAT]). However, the use of TAT has been associated with a 2- to 4-fold increase in the risk of major bleeding in observational and randomized controlled trials (RCTs).⁸,⁹ Practical decision-making in these patients therefore requires the assessment of stroke and bleeding risks in a pragmatic manner, using established risk stratification approaches.¹⁰,¹¹

KEY WORDS  acute coronary syndrome, atrial fibrillation, dual antithrombotic therapy, percutaneous coronary intervention, triple antithrombotic therapy

ABSTRACT  The use of triple antithrombotic therapy (TAT) consisting of an oral anticoagulant (OAC), aspirin, and a P2Y12 inhibitor in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) is associated with a high risk of bleeding. Recently, several randomized clinical trials tested the hypothesis as to whether dual antithrombotic therapy (DAT) regimens (consisting of an OAC and a single antiplatelet drug) may be safer in terms of bleeding events as compared with TAT. They also investigated the role of non–vitamin K antagonist oral anticoagulants (NOACs) as a part of DAT and TAT. The purpose of this review is to provide an overview of available evidence regarding the safety and efficacy of DAT compared with TAT regimens, international guidelines recommendations, knowledge gaps, and unmet needs in the management of patients with AF and ACS and/or undergoing PCI.
Recent evidence from RCTs showed that the use of dual antithrombotic therapy (DAT), consisting of an OAC plus a P2Y12 inhibitor, was associated with a significant reduction in major bleeding events as compared with TAT, with no significant increase in the rate of trial-defined major adverse cardiovascular events (MACEs) including myocardial ischemia, stent thrombosis, and death. Nevertheless, the enthusiasm for the use of DAT early after ACS and/or PCI is counterbalanced by a note of caution, since these results come from trials focused on treatment safety, not powered to provide evidence on the efficacy of DAT compared with TAT. Whether DAT should be used as a default treatment option in all AF patients with ACS and/or undergoing PCI is currently intensely debated.

In this review, we provide an overview of available evidence concerning combined antithrombotic therapies in patients with AF and ACS and/or undergoing PCI, outline international guideline recommendations, and discuss knowledge gaps and unmet needs in the management of patients with AF and ACS and/or undergoing PCI.

**Evidence summary**  
**Randomized controlled trials**  
Several RCTs have recently addressed the safety of omitting aspirin in combined antithrombotic treatment regimens in patients with ACS and/or undergoing PCI in whom long-term OAC use is indicated. The essential characteristics of those trials are shown in Table 1, whereas Tables S1 and S2 (Supplementary material) show the rates of safety and efficacy endpoints, respectively.

In the open-label WOEST (What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting) trial, patients with an indication for long-term OAC use and undergoing PCI were randomized to receive DAT (a VKA plus clopidogrel) or standard TAT (a VKA, clopidogrel, and aspirin). At a 1-year follow-up, there were significantly less bleeding events in the DAT arm, although the difference was mostly driven by minor bleeding, without differences in major bleeding events and in the rates of thrombotic events. Notably, the overall major bleeding rates were low in the WOEST trial. In the trial cohort, 162 patients (69%) had AF, TAT was continued for 12 months only in those implanted with a drug-eluting stent (DES; 65% of patients), proton pump inhibitors (PPIs) were not routinely used, and the trial was underpowered to assess efficacy outcomes (i.e., thrombotic events).

The first RCT that addressed the duration of TAT (a VKA, clopidogrel, and aspirin) was the ISAR-TRIPLE (Duration of Triple Therapy in Patients Requiring Oral Anticoagulation after Drug-Eluting Stent Implantation) trial. It compared 6 weeks versus 6 months of TAT in patients after PCI and with an indication for VKA use (in 84% of patients, AF and/or atrial flutter was an indication for VKA use). After the prespecified TAT period, clopidogrel was discontinued and patients were receiving a VKA plus aspirin. During the 9-month follow-up, there was no significant difference in the primary endpoint (a composite of death, myocardial infarction [MI], definite stent thrombosis or Thrombolysis in Myocardial Infarction [TIMI] major bleeding). The trial was underpowered to address the individual components of the primary endpoint. Nevertheless, the ISAR-TRIPLE trial showed that duration of TAT could be shortened in selected patients at high risk of bleeding. Another analysis of this cohort showed that patients showing an enhanced response to clopidogrel (as measured by adenosine diphosphate-induced platelet aggregation) had significantly higher rates of major bleeding and death. Following the approval of NOACs for stroke prevention in patients with AF, several RCTs investigated the safety of NOACs and aspirin discontinuation in patients requiring a combined antithrombotic therapy for AF and ACS and/or PCI.

In the open-label PIONEER-AF (Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI) trial, patients were randomized in a 1:1:1 ratio to: 1) rivaroxaban 15 mg (or rivaroxaban 10 mg in patients with moderate renal impairment) plus a P2Y12 inhibitor for 12 months; 2) rivaroxaban 2.5 mg twice daily and DAPT; or 3) standard TAT with a VKA plus DAPT in patients with AF and ACS (medically managed or with PCI) or elective PCI. A P2Y12 inhibitor was withdrawn from TAT after 1 month, 6 months, or 12 months, while aspirin was continued. After 12 months, the rates of bleeding events were significantly lower in the rivaroxaban-based treatment regimens compared with the standard TAT (i.e., a VKA plus DAPT). Although there were no significant differences in ischemic events including stroke, MI, and stent thrombosis, the number of these events was small, and the trial was not sufficiently powered to address individual efficacy components. Notably, neither dose of rivaroxaban used in that trial (that is, a reduced dose of 15 mg once daily or a very low dose of 2.5 mg twice daily) was tested in the landmark ROCKET AF (Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation) trial for the prevention of cardioembolic stroke or systemic embolism in patients with AF (of note, the ROCKET AF trial tested the 20-mg rivaroxaban dose once daily with dose reduction to 15 mg once daily in patients with creatinine clearance <50 ml/min). Full-dose rivaroxaban was not used in the PIONEER-AF trial based on the ATLAS ACS-TIMI 46 (Rivaroxaban Versus Placebo in Patients with ACS) study results, which showed an excess in the bleeding risk when rivaroxaban 20 mg was
aspirin plus a P2Y12 inhibitor in patients with AF and ACS (medically managed or with PCI) or elective PCI. The rates of the primary end-point of major or clinically relevant nonmajor (CRNM) bleeding were significantly lower with DAT consisting of dabigatran and a P2Y12 inhibitor. In contrast to the PIONEER-AF trial using the reduced 15-mg rivaroxaban dose, both dabigatran doses used in the RE-DUAL PCI trial were tested in the landmark RE-LY (Dabigatran Versus Warfarin in Patients with Atrial Fibrillation) trial for stroke prevention in patients with AF.

The RE-DUAL PCI trial was also underpowered to show the efficacy of DAT (dabigatran plus a P2Y12 inhibitor) in the prevention of MACE. The very low-dose rivaroxaban regimen was chosen based on the ATLAS ACS 2–TIMI 51 (Rivaroxaban in Patients with a Recent Acute Coronary Syndrome) trial results, which showed that adding rivaroxaban 2.5 mg twice daily to DAPT in patients with ACS resulted in significantly lower rates of the primary endpoint (a composite of cardiovascular death, MI, or stroke) in patients with ACS in sinus rhythm.

The RE-DUAL PCI (Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation) trial compared dabigatran 150 mg twice daily or 110 mg twice daily plus a P2Y12 inhibitor versus standard TAT that included a VKA plus aspirin plus a P2Y12 inhibitor in patients with AF and ACS (medically managed or with PCI) or elective PCI. The rates of the primary endpoint of major or clinically relevant nonmajor (CRNM) bleeding were significantly lower with DAT consisting of dabigatran and a P2Y12 inhibitor. In contrast to the PIONEER-AF trial using the reduced 15-mg rivaroxaban dose, both dabigatran doses used in the RE-DUAL PCI trial were tested in the landmark RE-LY (Dabigatran Versus Warfarin in Patients with Atrial Fibrillation) trial for stroke prevention in patients with AF. The RE-DUAL PCI trial was also underpowered to show the efficacy of DAT (dabigatran plus a P2Y12 inhibitor) in the prevention of MACE.

**Table 1** Main characteristics of the WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST-AF PCI trials

| Year of publication | WOEST | PIONEER AF-PCI | RE-DUAL PCI | AUGUSTUS | ENTRUST-AF PCI |
|---------------------|-------|---------------|------------|-----------|----------------|
| 2013                |       |               |            |           |                |
| 573                 | 2126  | 2725          | 4614       | 1506      |                |
| Randomization window after index event<sup>a</sup> | 4 hrs | 72 hrs | 120 hrs | 14 d | 5 d |
| Treatment strategies | VKA + P2Y12 inhibitor vs VKA + DAPT | Rivaroxaban 15 mg once daily + P2Y12 inhibitor vs rivaroxaban 2.5 mg twice daily + DAPT vs VKA + DAPT | Dabigatran 110 mg twice daily + P2Y12 inhibitor vs dabigatran 150 mg twice daily + P2Y12 inhibitor vs VKA + DAPT | Apixaban 5 mg twice daily + DAPT vs apixaban 5 mg twice daily + P2Y12 inhibitor vs VKA + DAPT vs VKA + P2Y12 inhibitor | Edoxaban 60 mg once daily + P2Y12 inhibitor vs VKA + DAPT |
| Clinical settings, % | Elective PCI 72.5 | 61.5 | 49.5 | 38.8 | 48 |
| | Primary PCI 27.5 | 38.5 | 50.5 | 37.3 | 52 |
| | Medically managed ACS 0 | 0 | 0 | 23.9 | 0 |
| P2Y12 inhibitor, % | Clopidogrel 100 | 94.4 | 87.9 | 92.6 | 92 |
| | Ticagrelor 0 | 4.3 | 12.1 | 6.2 | 7 |
| | Prasugrel 0 | 1.3 | 0 | 1.2 | 0.5 |
| TAT regimen duration, mo | 1–12 (BMS) or 12 (ACS and DES) | 1, 6, or 12 | 1 (BMS) or 3 (DES) | 6 | 1–12 |
| DAPT regimen | VKA + clopidogrel | OAC + aspirin | OAC + P2Y12 inhibitor | OAC + P2Y12 inhibitor | OAC + P2Y12 inhibitor |
| Follow-up, mo | 12 | 12 | 14 | 6 | 12 |
| Safety endpoint | Any bleeding event | A composite of TIMI major bleeding or minor bleeding | Major or CRNM ISTH-defined bleeding | Major or CRNM ISTH-defined bleeding | Major or CRNM ISTH-defined bleeding |
| MACE definition | A composite of death, MI, stroke, target vessel revascularization, and ST | A composite of death, MI or stroke, and ST | A composite of all-cause death or an ischemic event (including stroke, MI, SE, or nonelective revascularization) | A composite of all-cause death or an ischemic event (including stroke, MI, definite or probable ST, and urgent revascularization) | A composite of CV death or an ischemic event (including stroke, MI, definite ST, SE) |

<sup>a</sup> All patients received TAT in the period from the index event to randomization. In the AUGUSTUS and ENTRUST-AF PCI trials, the median (interquartile range) time from the index event to randomization was reported and was 6 (1–10) days and 45.1 (22.2–76.2) hours, respectively.

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; BMS, bare-metal stent; CRNM, clinically relevant nonmajor; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ISTH, International Society on Thrombosis and Haemostasis; MACE, major adverse cardiovascular event; MI, myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SE, systemic embolism; ST, stent thrombosis; TAT, triple antithrombotic therapy; TIMI, Thrombolysis in Myocardial Infarction; VKA, vitamin K antagonist
of thromboembolic events. Of note, the rates of thrombotic events including stent thrombosis were numerically the highest among patients receiving DAT consisting of dabigatran 110 mg twice daily and a P2Y12 inhibitor, thus questioning the efficacy of this combination, particularly in patients at higher risk of ischemia.

These 2 NOAC trials compared DAT consisting of a NOAC plus a P2Y12 inhibitor and TAT including warfarin plus DAPT, but neither assessed whether TAT with a NOAC plus DAPT would lead to a lower incidence of bleeding events than TAT consisting of warfarin plus DAPT. Overall, it could not be determined based on firm evidence that the lower rates of bleeding were associated with the use of a NOAC, aspirin discontinuation, or both. There is the ongoing COACH-AF-PCI (Dabigatran Versus Warfarin with NVAF Who Undergo PCI) trial that will compare dabigatran in TAT and the standard TAT with a VKA.

The double-blind AUGUSTUS (Antithrombotic Therapy after Acute Coronary Syndrome or PCI in VKA arms, although the overall number was low. At 6 months, ischemic event rates including stent thrombosis were higher in patients receiving TAT compared with a VKA in the respective DAT and TAT regimens. The study showed that patients who received apixaban-based treatments (either DAT or TAT) had significantly lower rates of International Society on Thrombosis and Haemostasis (ISTH) criteria–defined major or CRNM bleeding compared with the VKA-based DAT or TAT treatments. Nevertheless, the rates of bleeding-related hospitalizations were more than 2-fold higher in patients receiving TAT compared with DAT, and the lowest bleeding rates were observed among patients receiving apixaban, a P2Y12 inhibitor, and placebo, and the highest in those receiving a VKA, aspirin, and a P2Y12 inhibitor. At 6 months, ischemic event rates including stent thrombosis were higher in the DAT regimens than in the TAT regimens. Most of stent thrombosis events (approximately 80%) occurred in the first 30 days of PCI; the event rates were lower in aspirin versus placebo arms and apixaban versus VKA arms, although the overall number was low. The AUGUSTUS trial was also underpowered to assess the efficacy of DAT regimens for stent thrombosis and MI. Notably, the AUGUSTUS trial was the only one that included medically treated patients with ACS (n [%] = 1097 [23.9]), and pre-specified subgroup analysis showed consistently better safety and similar efficacy of apixaban versus VKA regimens in patients with medically managed ACS.

The open-label ENTRUST-AF PCI (Edoxaban-Based Versus Vitamin K Antagonist-Based Antithrombotic Regimen after Successful Coronary Stenting in Patients with Atrial Fibrillation) trial investigated DAT consisting of edoxaban 60 mg once daily and a P2Y12 inhibitor versus TAT consisting of a VKA plus DAPT in patients with AF and undergoing PCI. At 12 months, the primary endpoint (major or CRNM ISTH-defined bleeding) rate was significantly lower for DAT compared with TAT, with a nonsignificant difference in the rates of thrombotic events. Owing to the relatively small study population, the ENTRUST-AF PCI trial was underpowered to assess efficacy outcomes.

**Meta-analysis** Several meta-analyses of these RCTs were conducted in order to provide greater insight into the effects of specific treatment regimens regarding ischemic events. All of them have shown that DAT regimens are safer than TAT regimens not at the expense of the significantly higher rates of death, cardiovascular death, MACEs, and stroke, but have yielded conflicting results in terms of coronary ischemic events (ie, stent thrombosis and MI).

Lopes et al analyzed the WOEST, PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials (including a total of 10 026 patients) and showed that, in comparison with VKA-based DAT and TAT regimens, the NOAC-based DAT regimen was the safest combination regarding the trial-defined primary safety outcome, with no significant difference in the efficacy outcomes including coronary ischemic events. Of note, this analysis also included 1097 medically managed patients with ACS from the AUGUSTUS trial, thus possibly underestimating the effect of aspirin discontinuation on stent thrombosis. Indeed, in a meta-analysis of the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials (including a total of 9463 patients), Potpara et al reported a significant, 67% higher risk for stent thrombosis with DAT versus TAT regimens when medically managed patients with ACS were excluded from the analysis.

After the publication of the ENTRUST-AF PCI trial, the meta-analyses including all 4 trials of NOAC use also showed conflicting results concerning coronary ischemic events. For example, the meta-analysis of the WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST-AF PCI trials by Lopes et al (including a total of 11542 patients) demonstrated lower bleeding rates and no significant difference in coronary ischemic events when DAT was compared with TAT. The results were consistent when the NOAC-based DAT was compared with the VKA-based TAT with regard to stent thrombosis (odds ratio [OR], 1.3; 95% CI, 0.61–2.64) and MI (OR, 1.15; 95% CI, 0.84–1.55). Another meta-analysis of the PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST-AF PCI trials (including a total of 10 234 patients) by Gargiulo et al showed that DAT regimens were safer than TAT in terms of the primary safety endpoint of ISTH-defined major or CRNM bleeding (risk ratio [RR], 0.66; 95% CI, 0.56–0.78;
The use of more potent P2Y12 inhibitors in combination with non–vitamin K antagonist oral anticoagulants. In the RCTs investigating the safety of antithrombotic therapy, clopidogrel was the main P2Y12 inhibitor used in more than 90% of participants. Clopidogrel is a prodrug that needs to be effective, adding a proton pump inhibitor, avoiding the concomitant use of nonsteroidal anti-inflammatory drugs, and optimizing the VKA therapy (see TABLE 2).39

Knowledge gaps The timing of aspirin discontinuation after an index event In the RCTs mentioned above, the use of aspirin was allowed until randomization (TABLE 1). Hence, these RCTs were not examining a true DAT from the very beginning of ACS / PCI or elective PCI, and a possible residual effect of aspirin could have influenced the results in terms of treatment safety and efficacy.

Dual antithrombotic therapy in patients at high risk of cardiac ischemic events Patients at high risk of coronary stent thrombosis and/or recurrent MI were largely underrepresented in the RCTs investigating the safety of antithrombotic therapy.

What do international guidelines say? Current international guidelines and consensus documents agree that the duration of TAT should be minimized, balancing the patient’s ischemic and bleeding risks (see TABLE 2). As ticagrelor and prasugrel were underrepresented in RCTs, guidelines recommend that these agents should be avoided in combination with OACs, except when there is a clear reason for such treatment choice (eg, early stent thrombosis in patients receiving clopidogrel).31–34 Additional strategies that may mitigate the risk of bleeding in patients taking a combination of OACs and antiplatelet drugs include using the radial approach for coronary angiography, using the lowest dose of aspirin proven to be effective, adding a proton pump inhibitor, avoiding the concomitant use of nonsteroidal anti-inflammatory drugs, and optimizing the VKA therapy (see TABLE 2).39

The prespecified subanalysis of the RE-DUAL PCI trial showed a reduced bleeding risk with no significant difference in the rates of ischemic events when the dabigatran-based DAT was compared with the VKA-based TAT, irrespective of clinical or procedural factors including a lesion, complexity, or both and irrespective of the modified DAPT40 score (DAPT score ≥2 in 909 patients [33.4%]).41 The clinical and/or procedural complexity factors used in this analysis were based on the DAPT (Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents) trial risk factors.42 Clinical complexity factors included the presence of any of the following: ACS, acute ST-segment elevation MI, left ventricular ejection fraction <30%, and kidney failure (creatinine level ≥2 mg/dl or dialysis). The procedural (including lesion-related) factors included the presence of any of the following: more than 2 vessels stented, treatment of in-stent restenosis of a DES, prior brachytherapy applied to the target lesion, an unprotected left main lesion, more than 2 lesions in a single vessel, lesion length ≥30 mm, a bifurcation lesion with the side branch ≥2.5 mm, a vein bypass graft (segment or anastomosis), or a thrombus-containing lesion.42,43 The modified DAPT score used in that subanalysis included the following factors with the prespecified scoring: age, MI at presentation, prior PCI or prior MI, vein graft PCI, current smoking status, diabetes mellitus, and history of congestive heart failure or left ventricular ejection fraction <30%.41

In another prespecified subanalysis of the RE-DUAL PCI trial, the risks of bleeding and stroke were higher in older (age ≥75 years) patients with AF and undergoing PCI compared with those younger (age <75 years). While DAT with the 110-mg dabigatran dose twice daily compared with the VKA-based TAT reduced the risk of bleeding in both older and younger patients, DAT with the 150-mg dabigatran dose twice daily did not reduce the risk of bleeding in older patients as compared with the VKA-based TAT, and the bleeding risk remained lower in younger individuals. There was a trend towards a higher risk of ischemic events in older patients receiving DAT with the 110-mg dabigatran dose twice daily as compared with the VKA-based TAT, with no increased ischemic risk noted in younger patients. In the study arm receiving DAT with the 150-mg dabigatran dose twice daily, there was no significant difference in ischemic events as compared with the VKA-based TAT in both older and younger patients.44

In the RCTs investigating the safety of antithrombotic therapy, clopidogrel was the main P2Y12 inhibitor used in more than 90% of participants. Clopidogrel is a prodrug that needs...
biodtransformation through hepatic cytochrome P-450 (CYP) enzymes into an active metabolite, and around 30% of patients have a CYP2C19 polymorphism with consequent resistance to clopidogrel and a higher risk of MACEs including stent thrombosis. Whether this risk would be safely attenuated using a more potent P2Y12 inhibitor (ie, ticagrelor or prasugrel) in combination with an OAC is currently less well known, since patients receiving a more potent P2Y12 inhibitor were largely underrepresented in the RCTs of patients with AF and ACS and/or undergoing PCI.

A prespecified exploratory analysis of the RE-DUAL PCI trial showed that patients on ticagrelor (n [%] = 327 [12]) compared with those who received clopidogrel had not only significantly higher rates of bleeding but also higher rates of borderline significance, of ischemic events (a composite of death, thromboembolic events, or nonelective revascularization). Notably, the use of ticagrelor in the RE-DUAL PCI trial was at the physician’s discretion, and patients who received ticagrelor had a higher ischemic risk and clinical and procedural complexity (73% of patients in whom ticagrelor was prescribed presented with ACS) compared with those on clopidogrel. The ongoing RT-AF (Rivaroxaban in Patients with Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) trial will compare DAT
consisting of ticagrelor and rivaroxaban versus the VKA-based TAT in patients with AF undergoing PCI, and the CAPITAL PCI AF (The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention) nonrandomized study will investigate rivaroxaban and ticagrelor use in patients with AF and undergoing PCI.

**Other issues** Given the predictable dose-related anticoagulant effect of NOACs, a routine measurement of NOAC blood levels is not justified. Whether highly selected patients (eg, those with recurrent bleeding and/or ischemia) would benefit from NOAC blood level measurement is presently unclear.\(^{51}\)

**Conclusions** Optimizing antithrombotic therapy in patients with AF and ACS and/or undergoing PCI may be challenging and balancing the risks of bleeding and ischemic events is mandatory in each patient. The evidence shows that NOAC use, as an OAC strategy, is safer compared with the VKA-based treatment. This has been confirmed by results of clinical trials and real-world evidence supporting the safer profile of NOACs over VKAs, even in elderly patients with AF.\(^{52,53}\)

Whereas the use of DAT consisting of an OAC (a NOAC in particular) and a P2Y12 inhibitor has been associated with a significant reduction in major bleeding and intracerebral hemorrhage in comparison with TAT, this safety benefit may be countered by an increased risk of coronary ischemic events with DAT, especially in high-risk patients. Notably, the risk of cerebrovascular ischemic events and mortality was broadly comparable across all treatment regimens in the pertinent RCTs.

No evidence is available to inform the use of a “true” DAT without at least a very short initial course of TAT. While early discontinuation of aspirin (eg, within a few days from presentation) may be considered as a default, caution is required in patients at high risk of recurrent coronary ischemic events who could benefit from a longer TAT course. More evidence is needed to better define the optimal timing of aspirin discontinuation and the use of more potent P2Y12 inhibitors in combination with OACs.

**SUPPLEMENTARY MATERIAL**

Supplementary material is available at www.mp.pl/kardiologiapolska.

**ARTICLE INFORMATION**

**CONFLICT OF INTEREST** None declared.

**OPEN ACCESS** This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for non-commercial purposes only. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

**HOW TO CITE** Mihajlović M, Maričkić M, Kozieł M, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and/or undergoing percutaneous coronary intervention. Kardiol Pol. 2020; 78: 512-519. doi:10.33963/KP.15428

**REFERENCES**

1. Häm M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4: e001486.
2. Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017; 117: 1230-1239.
3. Prittcher RV, Bem D, Turner GM, et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. Thromb Haemost. 2019; 119: 294-307.
4. Hylek EM. Treatment persisten in atrial fibrillation: the next major hurdle. Thromb Haemost. 2018; 118: 2019-2018.
5. The AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J. 2002; 143: 991-1001.
6. Lip GY, Bevers DG. ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation. BMJ. 1995; 311: 1361-1363.
7. Steensig K, Olsen KKW, Thim T, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry. Thromb Haemost. 2018; 118: 2162-2170.
8. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170: 1433-1441.
9. van Reijn N, Heide-Jørgensen U, Lifring WM, et al. Major bleeding rates in atrial fibrillation patients: on single, dual, or triple antithrombotic therapy. Circulation. 2019; 139: 775-786.
10. Proietti M, Mijovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost. 2018; 118: 2014-2017.
11. Borre ED, Goode A, Raetz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018; 119: 2171-2187.
12. Dewilde WJ, Diribs T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-1115.
13. Fiedler KA, Maeng M, Mehlilj J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ESAR-TREBLE trial. J Am Coll Cardiol. 2015; 65: 1619-1629.
14. Goedel A, Fiedler KA, Mehlilj J, et al. Enhanced platelet inhibition by clopi-dogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. EuroIntervention. 2019; 15: 700-706.
15. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375: 2423-2434.
16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonval- vular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
17. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
18. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
19. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabi- gatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377: 1513-1524.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in pa- tients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
21. Antzehowski C, Brugada P, Brugada J, et al. Brugada syndrome: from cell to bedside. Current problems in cardiology. 2005; 30: 9-54.
22. Lopes RD, Heier G, Aronson R, et al. Antithrombotic therapy after acute coro- nary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019; 380: 1509-1524.
23. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
24. Yora AN, Alexander JH, Wojylka DM, et al. Hospitalization among patients with atrial fibrillation and a recent acute coronary syndrome or percutaneous coro- nary intervention treated with apixaban or aspirin: insights from the AUGUSTUS trial. Circulation. 2019; 140: 1960-1963.
25. Lopes RD, Leonardi S, Wojylka DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2020; 141: 781-783.
26. Windecker S, Lopes RD, Massaro T, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. Circulation. 2019; 140: 1921-1932.
27. Vrankic P, Valjgmić M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in
patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394: 1335-1343.

28 Guigliano RP, Nuff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104.

29 Lopes RD, Hong H, Harksamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019; 4: 747-755.

30 Potpara TS, Muppic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Euro. 2020; 22: 33-46.

31 Lopes RD, Hong H, Harksamp RE, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol. 2020; 5: 582-589.

32 Gargiulo G, Groot A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019; 40: 3757-3767.

33 Kirkhof P, Benussi S, Katech D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893-2962.

34 Valignieni M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. 2018; 39: 213-260.

35 Neumann FJ, Sousa-Uva M, Abelson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87-165.

36 Steffen J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagu- lants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330-1393.

37 January CT, Wann LS, Callins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019; 74: 104-132.

38 Knust J, Wijes W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41: 407-477.

39 Crowther MA, Elseboom JW. Dual and triple antithrombotic therapies: current patterns of practice and controversies. Kardiol Pol. 2018; 76: 937-944.

40 Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016; 315: 1733-1745.

41 Berry NC, Mauri L, Steg PG, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin tri- ple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. Circ Cardiovasc Interv. 2020; 13: e008349.

42 Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-2166.

43 Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplate- let therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary ar- tery lesions. Am Heart J. 2010; 160: 1035-1041.

44 Ten Berg JM, Steg PG, Bhatt DL, et al. Comparison of the Effect of Age (< 75 Versus >/= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran+Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin+Aspirin+Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol. 2020; 125: 735-743.

45 Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopido- grel is due to a metabolic activation by the hepatic cytochrome P450. JAMA. 1994; 72: 313-317.

46 Lau WK, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109: 166-171.

47 Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362.

48 Oldgren J, Steg PG, Hohnloser SR, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in patients with or without acute coronary syndrome: a subgroup analysis from the REDUAL PCI trial. Eur Heart J. 2019; 40: 1553-1562.

49 Gao F, Shen H, Wang ZJ, et al. Rationale and design of the RT-AF study. Euro- pac randomized trial: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and cor- onary artery disease undergoing percutaneous coronary intervention. Contemp Clin Trials. 2015; 43: 129-132.

50 Haisaguerre M, Estramiana E, Hecini M, et al. Mapping and ablation of ven- tricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003; 108: 925-928.